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Abstract
Background Ulcerative proctitis (UP) is a prevalent
condition associated with increased morbidity and mortal-
ity. Topical mesalamine (5-aminosalicylic acid [5-ASA])
inhibits inﬂammatory processes in UP.
Methods We evaluated effects of mesalamine 1-g supposi-
tory administered QHS compared with 500-mg suppository
administered BID on UP activity (e.g., disease extension/
mucosalappearance),remission,onsetofresponse,safetyand
compliance in 97 patients with UP. A 6-week, randomized,
multicenter, parallel-group, noninferiority study was con-
ducted (and published) with Disease Activity Index (DAI) at
week 6 as the primary efﬁcacy variable and individual com-
ponents of DAI at week 6 (i.e., stool frequency, rectal bleed-
ing, mucosal appearance, global assessment) as secondary
variables. Unreported outcomes were remission (DAI\3a t
weeks 3 and 6), disease extension, and complete response to
treatment (DAI = 0; post-hoc, exploratory analysis).
Results DAI values after 6 weeks were signiﬁcantly
reduced (±SD) from 6.6 ± 1.5 to 1.6 ± 2.3 (500-mg BID);
and from 6.1 ± 1.5 to 1.3 ± 2.2 (1-g QHS). Mucosal
appearance signiﬁcantly improved from baseline after 3 and
6 weeksoftreatmentfrom1.8 ± 0.5to0.8 ± 0.7and0.5 ±
0.7 (500-mg BID; P B 0.0062) and from 1.7 ± 0.5 to
0.9 ± 0.5 and 0.4 ± 0.6 (1-g QHS; P B 0.0001), respec-
tively. Remission was comparable (78.3–86.1%); onset of
response generally occurred within 3 weeks, and disease
extensionwasreduced([70%)after6 weeksinbothgroups.
Mesalamine was well tolerated. Compliance was[96%.
Conclusions Mesalamine 500-mg BID and 1-g QHS
suppositories are safe and effective for patients with UP.
Most patients reported signiﬁcant improvement within
3 weeks and UP remission and reduced disease extension
after 6 weeks of treatment. Validity of QHS administration
was conﬁrmed.
Keywords Mesalamine  Ulcerative proctitis 
Suppository  Inﬂammatory bowel disease
Introduction
Ulcerative colitis (UC) is a chronic bowel disease deﬁned
by rectosigmoid mucosal inﬂammation and associated with
immune system dysregulation [1–3]. Ulcerative proctitis
(UP), a cryptogenic subset of UC, is differentiated by
mucosal inﬂammation restricted to the rectum. Both
UC and UP are symptomatically characterized by rectal
bleeding, tenesmus, periodic diarrhea or constipation, and
rectal pain [1]. Between 1 and 15 in 10,000 Americans
have UC [1, 4], and up to 75% of newly diagnosed cases of
UC may be UP [1]. Conversely, UP may progress to UC in
up to 50% of affected patients [1].
The primary goals of managing UP include inducing
and maintaining remission and healing the mucosa [3, 5].
Although oral formulations of 5-aminosalicylic acid
(5-ASA), corticosteroids, and immunomodulators have
been used successfully for disease management [6–8], data
have demonstrated the effectiveness of topical formula-
tions of these agents for the treatment of patients with UP
[9–15]. Topical mesalamine (5-ASA delivered via sup-
pository), which has been available for nearly two decades,
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action, and interferes with the transcriptional activation of
genes encoding inﬂammatory mediators in the rectal mucosa
in patients with UP [2, 6–13, 15, 16]. Further, preclinical
studies have shown that topical mesalamine prevents the
proliferation of colorectal cancer cells [17–19]. While most
patients respond to BID dosing (i.e., one 500-mg mesala-
mine suppository in the morning and one at bedtime
[QHS]), studies have shown that patients prefer taking a
single 1-g mesalamine suppository QHS [10, 13].
These ﬁndings provided the basis for the selection of
mesalamine doses (i.e., a 500-mg suppository BID or a 1-g
suppository QHS) that were used in a 6-week, randomized
multicenter study in patients with UP [20]. In that study,
both mesalamine dosing regimens demonstrated compara-
ble efﬁcacy and safety, with similar compliance rates (only
intent-to-treat [ITT] data were presented) [20]. The data
reported herein are the results from additional analyses that
were performed on the original population and conﬁrm and
expand upon those previously reported outcomes.
Materials and Methods
Study Design
A multicenter, randomized, parallel-group, noninferiority
study was conducted to compare the efﬁcacy and safety of
a mesalamine 1-g suppository administered QHS and 500-
mg suppositories administered BID (in the morning and
QHS) in patients with active UP. The study protocol and
amendments were reviewed and approved before submis-
sion to the appropriate institutions and regulatory agencies,
and the trial was performed in accordance with the rules
of Good Clinical Practice and was compliant with the
Declaration of Helsinki.
Study Population
Eligible patients were male and non-pregnant non-lactating
females, 18–70 years of age, with rectally conﬁned UP
conﬁrmed by ﬂexible sigmoidoscopy/colonoscopy (within
7 days of baseline measurements), and graded by a Disease
Activity Index (DAI) value between 4 and 11 [21, 22].
Patients had mental and legal ability to provide written
informed consent and could be smokers or non-smokers,
but were not permitted to change their smoking habits
during the 6-week study period. Patients were excluded if
they had other digestive diseases (conﬁrmed by histology
and stool culture) that would interfere with DAI grading
[23–25]. Patients were also excluded if they had UC
that extended beyond the rectum (as determined by sig-
moidoscopy/colonoscopy), if they chronically used oral 5-
ASA ([4 g/day), any form of rectal 5-ASA, or any other
medication for UP in the month preceding baseline mea-
surements. The presence of clinically signiﬁcant renal or
hepatic impairment, urinary tract obstruction, coagulation
disorders or use of anticoagulant drugs, other serious
medical conditions, history of idiopathic pancreatitis, lack
of use of reliable contraception (in women of child-bearing
potential), and use of any experimental drug within 30 days
of enrollment also excluded patients from the study.
Efﬁcacy Evaluation
The primary objective of this study was to compare the
clinical efﬁcacy of two mesalamine suppository regimens in
the treatment of patients with mild-to-moderate UP. The
primary efﬁcacy variable was DAI after 6 weeks of treat-
ment. The DAI is a rating scale with four subscales: stool
frequency, rectal bleeding, mucosal visualization at endo-
scopy, and disease global assessment [21]. Each subscale
has four subdivisions of severity ranging from 0 (normal) to
3; the DAI score is the sum of all the subscales.
The secondary objectives of this study were to assess the
remission rate (DAI\3 at weeks 3 and 6), complete
response to mesalamine after 3 and 6 weeks of treatment
(DAI = 0), efﬁcacy of the therapeutic regimens after
6 weeks of treatment versus baseline, effects of a concur-
rent maintenance dose of oral 5-ASA, the individual sub-
scales of the DAI at week 6, and evaluation of safety and
tolerability [23, 24]. Length of disease extension was
recorded from endoscopy reports.
Efﬁcacy and Safety Measures and Procedures
Patients were enrolled in the screening process after con-
ﬁrmation of willingness to participate and submission of
informed consent. At the ﬁrst visit, patients were instructed
on how to complete the daily diary used to provide data for
the DAI. A complete physical examination (excluding a
genital/gynecologic examination, unless indicated) and
endoscopy (with one rectal biopsy sample obtained from the
most severely diseased area and one biopsy sample obtained
fromnormaltissueabovethisarea)wereperformed,medical
history and demographic data were recorded, and routine
hematologic, clinical chemistry, and pregnancy tests (if
indicated), as well as urinalysis were completed (Fig. 1).
Mucosal histology and/or stool cultures (demonstrating the
absenceofova,parasites,pathogens orClostridiumdifﬁcile)
conﬁrmed patient admissibility. If a patient started medi-
cation on the basis of a positive diagnosis of UP and was
later found negative by histology and/or culture, he or she
was excluded from the ITT and efﬁcacy analyses and was
considered only for the safety analysis.
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treatment (i.e., between days 22 and 28). Endoscopy was
performed and DAI was assessed by reviewing each
patient’s diary and by questioning each patient about his or
her symptoms over the previous 3 days (Fig. 1). Additional
and continuing adverse events (AEs) and concomitant
medications were recorded, and unused study medications
were collected. New mesalamine and patient diaries were
dispensed.
The third and ﬁnal visit was performed after 6 weeks of
treatment (i.e., between days 43 and 49) or as an end-of-
treatment visit for patients who did not complete the trial
(e.g., dropouts, randomized screening failures). Physical
examination and the clinical laboratory tests (hematology,
biochemistry, urinalysis, pregnancy tests) performed at the
ﬁrst visit were repeated. Another endoscopy was performed
and the DAI value was recalculated by reviewing each
patient’s diary, and patients were questioned about any
symptoms experienced over the previous 3 days. AEs and
concomitant medications were recorded, and unused study
medications were retrieved (Fig. 1).
Compliance
Compliance was evaluated by suppository count at the
second and last visits.
Statistical Analyses
Sample size calculations and justiﬁcations were based upon
the ability to detect a difference of one DAI unit in the
primary end point. After consideration of patient dropouts
and withdrawals, it was calculated that 100 patients would
be required for the study (with 50 patients randomized to
each treatment; a = 0.05, power = 80%). Patients were
randomly assigned to treatment groups in blocks of ﬁve.
The study was open label.
The noninferiority of mesalamine 1 g QHS versus
500 mg BID was assessed through the following hypoth-
esis: H01: U1-U2 C 1.00 and H11: U1-U2\1.00. U1 and
U2 represented the mean DAI value at week 6 in patients
taking 1 g and 500 mg BID, respectively. A two-sided 90%
conﬁdence interval based on the comparison (U1-U2) was
derived using the least square means from the ANCOVA
model [26]. If the upper bound of this conﬁdence interval
was\1.00, it could be concluded that mesalamine 500 mg
BID was at least as effective as mesalamine 1 g HS (i.e.,
non-inferiority).
Treatment by pooled site and baseline interaction terms
were added separately. A signiﬁcant interaction term (at
0.1 level) was included in the ﬁnal model. Missing DAI
data were estimated by the last-observation-carried-for-
ward method for the ITT analysis.
All secondary efﬁcacy parameters were evaluated in
both the ITT and PP populations. The number and per-
centage of patients achieving remission (DAI\3 at weeks
3 and 6) were presented descriptively within each treatment
group, and the remission rate was tested using Fisher’s
exact test. Complete response to the study drug (DAI = 0)
was assessed after 6 weeks of therapy in each treatment
group by comparing DAI changes at weeks 3 and 6 using a
two-sided paired Student’s t test. The therapeutic response
(DAI change at week 6) in patients receiving a mainte-
nance dose of oral 5-ASA (B4 g/day) compared with
patients not receiving oral 5-ASA was assessed in both
treatment groups using a Wilcoxon rank-sum test. The
efﬁcacy of the two mesalamine regimens was also assessed
by comparing the DAI scores at baseline and week 6 using
a two-sided paired Student’s t test and Pearson correlation
(Spearman rank correlation if underlying assumptions were
not met). The individual subscales of the DAI at week 6
were analyzed using an ANCOVA model and within-
treatment comparisons. Length of disease extension was
recorded a posteriori from individual endoscopy reports
Mesalamine 500 mg Suppository BID
Mesalamine1 g Suppository QHS
BASELINE EVALUATION
￿ Complete medical history 
￿ Physical examination
￿ Routine hematology, urinalysis, serum chemistry  
and serum pregnancy test (if warranted)
￿ Disease Activity Index (DAI) evaluation
￿ Endoscopy performed (flexible sigmoidoscopy or   
colonoscopy)
FOLLOW-UP AFTER 3 WEEKS
￿ DAI evaluation
￿ Endoscopy performed (flexible  
sigmoidoscopy or colonoscopy)
￿ Adverse events and concomitant 
medications recorded
FOLLOW-UP AFTER 6 WEEKS
￿ Complete medical history 
￿ Physical examination
￿ Routine hematology, urinalysis, serum 
chemistry and serum pregnancy test (if   
performed at baseline)
￿ DAI evaluation
￿ Endoscopy performed (flexible sigmoidoscopy
or colonoscopy)
￿ Adverse events and concomitant medications 
recorded
Fig. 1 Investigational plan
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123and analyzed in an exploratory manner. Only descriptive
statistics were provided for safety parameters.
Results
Patient Disposition
Ninety-nine patients were recruited for this study, but two
patients did not receive mesalamine, leaving 97 patients in
the safety population (reported earlier [20]). Ten other
patients did not meet inclusion or exclusion criteria, leav-
ing 87 patients in the ITT population (Table 1). Eighty-
three patients received the respective mesalamine treatment
regimens and completed the study. Eighty-one patients
were included in the PP analysis; 14 patients did not
complete the 6-week study (Table 1).
Patient Demographics and Baseline Characteristics
Treatment groups did not differ signiﬁcantly with respect
to age or other baseline demographics between the ITT
(reported earlier [20]) and PP populations (Table 2). A
comparable percentage of patients in both treatment groups
in the ITT and PP populations had a similar medical history
and time since onset of UP (Table 2). There were no
patients that were classiﬁed with active chronic colitis
secondary to Crohn’s disease or active colitis that was
inconsistent with inﬂammatory bowel disease (Table 2).
Primary Efﬁcacy Evaluations
The use of mesalamine suppositories administered 500 mg
BID or 1 g QHS reduced DAI values from baseline at week
3 and further reduced DAI values at week 6 in both the ITT
(reported earlier [20]) and PP populations (Table 3). The
between-group treatment differences in DAI values in
weeks 3 and 6 were not statistically signiﬁcant in the ITT
or PP populations. As the upper bound of the conﬁdence
interval [-1.03; 0.69] was \1.00 unit, previously deﬁned
as clinical signiﬁcance, it could be concluded that mesal-
amine 500 mg BID is as effective as 1 g QHS; these results
were conﬁrmed in both the ITT and PP populations.
Secondary Efﬁcacy Evaluations
Treatment with mesalamine suppositories administered
500 mg BID and 1 g QHS improved individual compo-
nents of the DAI after 3 weeks and furthered improved
DAI values after 6 weeks. There was no difference
between the mesalamine treatment groups in the ITT
(reported earlier [20]) and PP populations with respect to
stool frequency, rectal bleeding, endoscopic appearance, or
global assessment (Table 4). Mucosal appearance was
almost normal in both groups after 6 weeks of treatment in
the ITT population. Further, there were no signiﬁcant dif-
ferences in remission rates after 3 weeks (*55%) or
6 weeks (*80%) of mesalamine therapy between treat-
ment groups in both the ITT and PP populations (Table 4).
The time to onset of a clinical response, ﬁrst assessed by
comparing the mean DAI values at week 3 with values at
baseline (Table 3), was statistically different (P\0.0001
for the ITT and PP populations; data not shown) after
3 weeks of mesalamine therapy in both treatment groups,
demonstrating that most patients responded within 3 weeks
of the treatment initiation. Further, when comparing mean
DAI values at weeks 3 and 6 (Table 3), data showed that the
responsetomesalaminewasstillincreasing(P B 0.0006for
both treatment groups in the ITT and PP populations; data
not shown). There was no statistically signiﬁcant difference
in DAI values in either the mesalamine treatment group in
the ITT or PP populations among patients who were or were
not receiving oral 5-ASA maintenance therapy (data not
shown).
Exploratory post-hoc analyses showed that the length of
disease extension was reduced from 12.4 ± 5.4 cm
(mean ± SD) at baseline to 3.5 ± 7.8 cm at week 6 in the
Table 1 Patient disposition
Patient descriptions Treatment Total
500 mg
BID
1g
QHS
Patients recruited –– 99
Did not receive study medication –– 2
Patients included in safety population 53 44 97
Patients who completed study 45 38 83
Patients who did not complete study 8 6 14
AEs 2 0 2
Withdrew consent 0 2 2
Lost to follow-up 1 0 1
Protocol violation 1 1 2
Other 2 3 5
Unknown 2 0 2
Patients included in ITT population 48 39 87
Patients excluded from ITT population 6 6 12
Did not receive study medication 1 1 2
Did not meet the inclusion/exclusion
criteria
55 1 0
Patients included in the PP population 46 35 81
Patients excluded from the PP analysis 8 10 18
Not included in the ITT population 6 6 12
Treatment failures 2 2 4
Overall compliance\75% 0 2 2
AE adverse event, ITT intent-to-treat, PP per-protocol
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ITT population Treatment
500 mg BID (n = 48) 1 g QHS (n = 39)
n % n %
Patient characteristics
Male 22 45.8 14 35.8
Female 26 54.2 25 64.2
Mean age, years (SD) 39.3 (13.5) 39.7 (13.8)
Caucasian 43 89.6 33 84.6
African American 3 6.2 1 2.6
Asian 0 0 3 7.7
Other 2 4.2 2 5.1
Mean weight, kg (SD) 73.1 (19.0) 76.6 (16.6)
Mean height, cm (SD) 169.6 (10.5) 168.4 (9.0)
History of UP
Yes 31 64.6 26 66.7
No 17 35.4 13 33.3
Mean time since onset, year (SD) 4.5 (5.9) 4.2 (4.0)
Endoscopy performed
Yes 48 100 39 100
No 0 0 0 0
Rectum
Normal 0 0 0 0
Presence of UP 48 100 39 100
Sigmoid
Normal 47 97.9 39 100
Presence of UP 1 2.1 0 0
Biopsies performed
Yes 48 100 39 100
No 0 0 0 0
Acute colitis inconsistent with IBD 0 0 0 0
Active chronic colitis (nonspeciﬁc IBD) 32 66.7 33 84.6
Active chronic colitis (consistent with UC) 2 4.2 1 2.6
Active chronic colitis (Crohn’s disease) 0 0 0 0
Nonspeciﬁc histologic conclusion 14 29.1 5 12.8
PP population 500 mg BID (n = 46) 1 g QHS (n = 35)
n % n %
Patient characteristics
History of UP
Yes 29 63.0 22 62.9
No 17 37.0 13 37.1
Mean time since onset, year (SD) 4.7 (6.1) 4.5 (4.2)
Endoscopy performed
Yes 46 100 35 100
No 0 0 0 0
Rectum
Normal 0 0 0 0
Presence of UP 46 100 35 100
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baseline to 1.5 ± 3.2 cm at week 6 in the 1 g QHS group
(Table 4). After 6 weeks of 500 mg BID therapy, 22
patients (41.5%) and 29 patients (54.7%) reported both
complete response and resolved disease extension,
respectively, compared with 15 patients (34%) and 25
patients (56.8%), respectively, in the 1 g QHS group.
Treatment Compliance
Compliance from ﬁrst to last dose in both treatment groups
in the ITT and PP populations was[96% (Table 4).
Safety Evaluation
Thirty patients (56.9%) in the mesalamine 500 mg BID
group and 24 patients (54.5%) in the mesalamine 1 g QHS
groupreportedtreatment-emergentAEs(TEAEs)(Table 5).
The most commonly reported TEAEs (reported earlier [20])
were in the gastrointestinal system (abdominal pain, ﬂatu-
lence, diarrhea, nausea) and the central nervous system
(headache) (Table 5). Eight TEAEs classiﬁed as severe
included abdominal pain (one patient in each treatment
group), abdominal distension, frequent bowel movements,
rectal hemorrhage, diarrhea, headache, and bronchospasm
(all in the mesalamine 1 g QHS group). Three patients
withdrew from the study because of treatment-limiting
TEAEs (bronchospasm, increased headache intensity,
worsening of clinical symptoms). No serious TEAEs were
reported, and no deaths occurred during the study.
Discussion
While UP is associated with increased morbidity and
mortality [1], few treatment guidelines have been published
[3, 27]. Goals of therapy for UP call for mitigation of
symptoms, including the reduction of rectal mucosal
inﬂammation, prevention of ﬂare-ups, and disease relapse
[3]. One major reason for relapse is lack of treatment
compliance [28]. Studies have shown that 47–86% of
patients with UP will relapse if they remain untreated for
1 year [1].
Table 3 Primary efﬁcacy results
Treatment
group
n DAI score
at baseline (SD)
n Mean DAI score
at week 3 (SD)
Between-group
P value
at week 3
n Mean DAI value
at week 6 (SD)
Between-group
P value
at week 6
ITT population
500 mg BID 48 6.6 (1.5) 48 2.5 (2.3) 0.8689 46 1.60 (2.30) 0.7292
1 g QHS 39 6.1 (1.5) 37 2.5 (1.7) 36 1.30 (2.20)
PP population
500 mg BID 46 6.6 (1.5) 46 2.4 (2.1) 0.8232 46 1.59 (2.30) 0.7394
1 g QHS 35 6.2 (1.5) 35 2.4 (1.7) 35 1.31 (2.19)
DAI disease activity index, ITT intent-to-treat, PP per-protocol, SD standard deviation
Table 2 continued
PP population 500 mg BID (n = 46) 1 g QHS (n = 35)
n % n %
Sigmiod
Normal 45 97.8 35 100
Presence of UP 1 2.2 0 0
Biopsies performed
Yes 46 100 35 100
No 0 0 0 0
Acute colitis inconsistent with IBD 0 0 0 0
Active chronic colitis (nonspeciﬁc IBD) 31 67.4 29 82.9
Active chronic colitis (consistent with UC) 2 4.3 1 2.9
Active chronic colitis (Crohn’s disease) 0 0 0 0
Nonspeciﬁc histological conclusion 13 28.3 5 14.2
IBD inﬂammatory bowel disease, ITT intent-to-treat, PP per-protocol, SD standard deviation, UC ulcerative colitis, UP ulcerative proctitis
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logic agents and antibiotics, alone or in combination, have
been incorporated into UP treatment algorithms [1, 3],
although new management strategies continue to emerge.
Topical medications/suppositories containing 5-ASA [29],
immunomodulators (e.g., tacrolimus) [11], and biologic
agents (e.g., inﬂiximab) [30] can prevent or mitigate the
cascade of inﬂammatory events in the rectal mucosa,
and reduce the morbidity and mortality associated with
UP [3, 7]. Recommendations and strategies for the
treatment of UP are shifting to incorporate these for-
mulations [3, 6].
Guidelines have advocated the use of rectally adminis-
tered mesalamine over topical steroids or oral 5-ASA for
Table 4 Secondary efﬁcacy and other results
Evaluations 500 mg BID 1 g QHS
Baseline Week 3 Week 6 Baseline Week 3 Week 6
ITT population
Stool frequency, mean value (SD) 1.5 (0.9) 0.8 (0.9) 0.5 (0.8) 1.2 (1.0) 0.5 (0.8) 0.4 (0.7)
Rectal bleeding, mean value (SD) 1.7 (0.6) 0.4 (0.6) 0.3 (0.5) 1.7 (0.7) 0.3 (0.6) 0.2 (0.6)
Mucosal appearance, mean value (SD) 1.8 (0.5) 0.8 (0.7) 0.5 (0.7) 1.7 (0.5) 0.9 (0.5) 0.4 (0.6)
General well-being, mean value (SD) 1.6 (0.5) 0.7 (0.7) 0.3 (0.6) 1.5 (0.5) 0.8 (0.6) 0.4 (0.7)
Total DAI score, mean value (SD) 6.6 (1.5) 2.5 (2.3) 1.6 (2.3) 6.1 (1.5) 2.5 (1.7) 1.3 (2.2)
Disease extent, cm (SD) 12.4 (5.4) 6.0 (7.5) 3.5 (7.8) 10.5 (4.2) 5.2 (4.6) 1.5 (3.2)
Patients achieving remission (%) N/A 56.3 78.3 N/A 54.1 86.1
Compliance (%) N/A 96.6 96.3 N/A 98.0 97.2
PP population
Stool frequency, mean value (SD) 1.5 (0.9) 0.7 (0.8) 0.5 (0.8) 1.2 (1.1) 0.5 (0.8) 0.4 (0.7)
Rectal bleeding, mean value (SD) 1.7 (0.6) 0.3 (0.5) 0.3 (0.5) 1.7 (0.7) 0.3 (0.6) 0.2 (0.6)
Visualization at endoscopy, mean value (SD) 1.8 (0.5) 0.7 (0.7) 0.5 (0.7) 1.7 (0.6) 0.9 (0.5) 0.4 (0.6)
General well-being, mean value (SD) 1.6 (0.5) 0.7 (0.7) 0.3 (0.6) 1.5 (0.5) 0.7 (0.6) 0.3 (0.7)
Total DAI score, mean value (SD) 6.6 (1.5) 2.4 (2.1) 1.6 (2.3) 6.2 (1.5) 2.4 (1.7) 1.3 (2.2)
Disease extent, cm (SD) 12.4 (5.4) 5.5 (7.4) 3.5 (7.8) 11.1 (4.2) 5.1 (4.6) 1.6 (3.2)
Patients achieving remission (%) N/A 57.0 78.0 N/A 57.0 86.0
Compliance (%) N/A 97.3 97.2 N/A 97.3 97.9
ITT intent-to-treat, N/A not available, PP per-protocol, SD standard deviation
Table 5 TEAEs in[5% of the safety population
TEAEs by system organ class Treatment
500 mg BID (n = 53) 1 g QHS (n = 44)
n % n %
Gastrointestinal disorders 10 18.9 7 15.9
Abdominal pain 3 5.7 2 4.5
Flatulence 3 5.7 2 4.5
Diarrhea 2 3.8 1 2.3
Nausea 2 3.8 1 2.3
Nervous system disorders 9 17.0 8 18.2
Infections and infestations 5 9.4 7 15.9
Investigations 7 13.2 2 4.5
General disorders and administration site conditions 3 5.7 3 6.8
Musculoskeletal and connective tissue disorders 2 3.8 3 6.8
Respiratory, disorders 3 5.7 2 4.5
Skin and subcutaneous disorders 2 3.8 2 4.5
Reproductive system and breast disorders 3 5.7 0 0.0
TEAE treatment-emergent adverse event
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refractory)distalUC[3],andstudieshaveshownthattopical
mesalamine is effective for symptomatic treatment [31],
timely induction, and maintenance of remission in patients
withUP[1,7,14,22,31,32].Inone4-week open-labeltrial,
clinical remission was reported in 84% of patients (n = 50)
treated with mesalamine suppositories QHS and in 80% of
patients treated BID [10]. Data from a similar study in 251
patients with cryptogenic proctitis showed that mesalamine
suppositories administered 500 mg BID or 1 g QHS were
equallyeffectiveinmitigatingthesymptomsofUP[13].The
capacity of topical mesalamine to lower DAI values may be
associated with its beneﬁcial effects on rectal mucosal
integrity, prostanoid production, and other mediators of
mucosal inﬂammation [2, 17, 33–35]. Further, the onset of
clinical response usually occurswithin3 weeks oftreatment
initiation. Remission rates documented in our study
(*80%) are greater than those reported elsewhere (*70%)
[29]. As in previously reported safety data [20], most of the
TEAEs in this trial were gastrointestinal or central nervous
system in nature, with no serious TEAEs associated with
mesalamine treatment.
While topical pharmacotherapies, including mesalamine
suppositories,canreducediseaseactivityinpatientswithUP
[3], the way in which these agents are administered can
compromise patients’ compliance and increase the overall
costs of treatment (secondary to the costs of treating disease
relapse and progression). In one multicenter study, 72
patients with UP who experienced C2 relapses within the
past year or had achieved remission within the previous
3 months were given oral 5-ASA daily and either a 5-ASA
enema or a placebo enema twice weekly for 1 year [36]. At
the end of the study, patients treated with oral and rectal
5-ASA experienced signiﬁcantly fewer relapses than did the
placebo-treated controls (P = 0.036). Given the reduced
overall need for medication to manage disease relapse,
pharmacoeconomic analysis of the data showed a favorable
cost-effectiveness ratio for the combination of oral and
rectal 5-ASA [36]. Data from a similar study in 42 patients
with UC who were treated with either oral 5-ASA and
5-ASA enemas or oral 5-ASA alone twice weekly for a
median of 6 years showed a signiﬁcant reduction in the
numberandincidenceofrelapsesinthepatientswhoreceived
the combined oral and rectal 5-ASA treatment regimen
(*40%;P\0.034)[37].Althoughadministrationdrugcosts
were higher for rectal than for oral 5-ASA, the overall cost of
relapse and hospitalization expenses decreased substantially
(*50%) in the population studied [37]. Further, the phar-
macologic treatment of patients with UP is associated with
lower rates of morbidity and mortality than are the various
surgical procedures currently being investigated [38].
The high rate of compliance reported by both mesala-
mine suppository treatment groups ([95%) in this study
compares favorably with compliance levels reported in
other studies [10, 13], and shows that patients are willing
to self-administer suppositories to manage their UP.
However, recent compliance data have shown that
reducing the frequency of administration (i.e., from BID
to QHS) signiﬁcantly improves adherence to treatment
[28]. The difﬁculty in retaining morning suppositories
reported in a previous study [10] was overcome with
QHS dosing.
A strength of this study was the use of the DAI, which
has been validated in other clinical trials. The 6-week
treatment duration of this study afforded an opportunity to
extend the efﬁcacy and safety assessment of mesalamine
and provide some insight into the number of suppositories
a patient may be willing to self-administer in a day. Lim-
itations of the study include the relatively small sample
size, the open-label design, the potentially compromised
calculation of compliance via suppository count, the lack
of a placebo run-in phase and/or a control group, and an
accurate evaluation of the onset of response or the time to
maximal response.
In conclusion, the results from this study conﬁrm the
efﬁcacy and safety of mesalamine suppositories when
administered at 500 mg BID or 1 g QHS for the treatment
of patients with active mild-to-moderate UP. Most patients
reported onset of response within 3 weeks and UP remis-
sion and reduced disease extension after 6 weeks of ther-
apy, indicating that a 6-week treatment period should be
recommended. The validity of a more convenient timing of
suppository administration (QHS rather than BID) was also
conﬁrmed, and this once-daily dosing should increase
compliance to mesalamine therapy and further improve
clinical outcomes for patients with UP. Future studies are
needed to quantify the beneﬁts of extending treatment with
mesalamine beyond 6 weeks and to examine remission in
treatment-naı ¨ve, newly diagnosed patients with UP.
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